Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Bolder BioTechnology General Information
Bolder BioTechnology has demonstrated positive Phase 1 results for its lead candidate BBT‑015—a long‑acting G-CSF analog—showing increased potency and safety in healthy volunteers. Other programs are at preclinical or research stages targeting large markets with unmet needs.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Boulder, Colorado
United States
United States
Drug Pipeline
BBT-015
Phase 1Key Partnerships
Strategic alliances with corporate partners intended for commercialization but no specific partners named publicly as of now
Bolder BioTechnology Funding
No funding data available
To view Bolder BioTechnology's complete valuation and funding history, request access »